AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12634966 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic no reflow
Number of subjects: 117
Study 10815576 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health promotion programme
Number of subjects: 500
Study 10815576 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 500
Study 7557599 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative adjuvant chemotherapy (VBP scheme)
Number of subjects: 230
Study 7557599 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery without preoperative adjuvant chemotherapy (Control)
Number of subjects: 230
Study 7557599 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative adjuvant chemotherapy
Number of subjects: 230
Study 2148321 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of glucosyltransferase (GTF) combined with aluminum phosphate (AP) daily for 5 days.
Number of subjects: 20
Study 7387491 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine mesylate (2.5 to 20.0 mg daily)
Number of subjects: 8
Study 7387491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7387491 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine mesylate (after cessation of therapy)
Number of subjects: 8
Study 31609716 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk‐based vibrotactile sensory augmentation (SA) during balance exercises
Number of subjects: 8
Study 31609716 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - balance training without SA
Number of subjects: 8
Study 29432350 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 180
Study 26893187 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg p.o. once daily for 52 weeks
Number of subjects: 120
Study 24527605 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN)
Number of subjects: 82
Study 24527605 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (Control)
Number of subjects: 82
Study 22613427 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA group)
Number of subjects: 24
Study 22613427 — intervention group
Group type: COMPARATOR
Intervention: Epidural anaesthesia (EA group)
Number of subjects: 24
Study 20942274 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture
Number of subjects: 60
Study 20942274 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study 17507264 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified triangular flap
Number of subjects: 32
Study 17507264 — intervention group
Group type: COMPARATOR
Intervention: Buccal envelope flap
Number of subjects: 32
Study 16042664 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol + Telithromycin (800 mg)
Number of subjects: 24
Study 16042664 — intervention group
Group type: COMPARATOR
Intervention: Sotalol + Placebo
Number of subjects: 24
Study 12177257 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation (donors)
Number of subjects: 96
Study 12177257 — intervention group
Group type: COMPARATOR
Intervention: No preoperative autologous blood donation (nondonors)
Number of subjects: 96
Study 9863281 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose etretinate combined with eicosapentaenoic acid
Number of subjects: 40
Study 9863281 — intervention group
Group type: COMPARATOR
Intervention: Low-dose etretinate alone
Number of subjects: 40
Study 8548058 — intervention group
Group type: EXPERIMENTAL
Intervention: Human galanin (hGAL) infusion (80 pmol.kg‐1.min‐1) for 60 minutes
Number of subjects: 9
Study 1978443 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulins (0.4 g/kg body weight IVIG every other week for 26 weeks)
Number of subjects: 30
Study 1978443 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin 0.03% every other week for 26 weeks)
Number of subjects: 30
Study 103182 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% aqueous solution of sodium cromoglycate
Number of subjects: 37
Study 7263746 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation using Garden screws
Number of subjects: 218
Study 7263746 — intervention group
Group type: EXPERIMENTAL
Intervention: Thompson hemiarthroplasty through a posterior (Moore) approach
Number of subjects: 218
Study 7263746 — intervention group
Group type: EXPERIMENTAL
Intervention: Thompson hemiarthroplasty through an anterolateral (McKee) approach
Number of subjects: 218
Study 30683457 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose colchicine (0.5 mg/day)
Number of subjects: 28
Study 29493714 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on skin-protective behavior
Number of subjects: 756
Study 29493714 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 756
Study 27173818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (letter sent to patients and general practitioners)
Number of subjects: 248
Study 27173818 — intervention group
Group type: COMPARATOR
Intervention: Control group (care-as-usual)
Number of subjects: 248
Study 25225745 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/kg
Number of subjects: 291
Study 25225745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 22172725 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoprotegerin (OPG) measured at baseline
Number of subjects: 1889
Study 20839670 — intervention group
Group type: EXPERIMENTAL
Intervention: Transepithelial treatment (group 1)
Number of subjects: 100
Study 20839670 — intervention group
Group type: EXPERIMENTAL
Intervention: Subepithelial treatment (group 2)
Number of subjects: 100
Study 16730113 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion via a two-way catheter
Number of subjects: 86
Study 15906755 — intervention group
Group type: EXPERIMENTAL
Intervention: LAC+CET (lansoprazole, amoxicillin, clarithromycin, and cetraxate)
Number of subjects: 55
Study 15906755 — intervention group
Group type: EXPERIMENTAL
Intervention: LEFT (LAC for 7 days in a horizontal body position on the left side)
Number of subjects: 55
Study 15906755 — intervention group
Group type: COMPARATOR
Intervention: LAC (lansoprazole, amoxicillin, and clarithromycin)
Number of subjects: 55
Study 12002492 — intervention group
Group type: EXPERIMENTAL
Intervention: LARS artificial ligament
Number of subjects: 53
Study 12002492 — intervention group
Group type: COMPARATOR
Intervention: ipsilateral bone‐patellar‐tendon‐bone autograft
Number of subjects: 53
Study 10445773 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% with 2% lidocaine and hyaluronidase 15 IU x mL(‐1)
Number of subjects: 90
Study 10445773 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.75% with 2% lidocaine and hyaluronidase 15 IU x mL(‐1)
Number of subjects: 90
Study 7790241 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+ETA (radiotherapy plus etanidazole)
Number of subjects: 504
Study 7790241 — intervention group
Group type: COMPARATOR
Intervention: RT (radiotherapy alone)
Number of subjects: 504
Study 2192405 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% (n = 24)
Number of subjects: 65
Study 2192405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% (n = 21)
Number of subjects: 65
Study 2192405 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine 1% (n = 20)
Number of subjects: 65
Study 393081 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐(3‐pyridyl) tetrazole
Number of subjects: 15
Study 29880098 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual compression
Number of subjects: 589
Study 29880098 — intervention group
Group type: COMPARATOR
Intervention: Mechanical compression
Number of subjects: 589
Study 27653268 — intervention group
Group type: EXPERIMENTAL
Intervention: 7th Generation (Ormco) lingual brackets
Number of subjects: 46
Study 27653268 — intervention group
Group type: EXPERIMENTAL
Intervention: STb (Ormco) lingual brackets
Number of subjects: 46
Study 25312449 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 145 μg
Number of subjects: 1271
Study 25312449 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 290 μg
Number of subjects: 1271
Study 25312449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1271
Study 24300203 — intervention group
Group type: EXPERIMENTAL
Intervention: Home enteral nutrition
Number of subjects: 82
Study 24300203 — intervention group
Group type: COMPARATOR
Intervention: Hospital enteral nutrition
Number of subjects: 82
Study 24300203 — intervention group
Group type: COMPARATOR
Intervention: Normal control
Number of subjects: 82
Study 20958119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 μg b.i.d.
Number of subjects: 365
Study 20958119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 640 μg b.i.d.
Number of subjects: 365
Study 20958119 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 365
Study 19999219 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low pressure suction (Group I)
Number of subjects: 100
Study 19999219 — intervention group
Group type: COMPARATOR
Intervention: Water seal only (Group II)
Number of subjects: 100
Study 16864166 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT)
Number of subjects: 1046
Study 16864166 — intervention group
Group type: COMPARATOR
Intervention: Control (no postoperative RT)
Number of subjects: 1046
Study 14657866 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum progesterone levels (mean 81.0 nmol/L in asthmatic children)
Number of subjects: 254
Study 14657866 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum estradiol levels (mean 7.87 nmol/L in asthmatic children)
Number of subjects: 254
Study 14657866 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum free estradiol levels (mean 149.5 pmol/L in asthmatic children)
Number of subjects: 254
Study 10714839 — intervention group
Group type: COMPARATOR
Intervention: Coracoid approach (C)
Number of subjects: 60
Study 10714839 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary approach (A)
Number of subjects: 60
Study 9179519 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 0
Study 9179519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9179519 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine and Placebo
Number of subjects: 0
Study 8210915 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin‐2 (rIL‐2) activated spleen-derived lymphokine‐activated killer (LAK) cells
Number of subjects: 0
Study 8210915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of Adriamycin followed by LAK cells
Number of subjects: 0
Study 3535544 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual tapering of alprazolam
Number of subjects: 10
Study 3535544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31713265 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVE (text messaging intervention); 1-2 health-related text messages per day over 16 weeks
Number of subjects: 61
Study 31713265 — intervention group
Group type: COMPARATOR
Intervention: AYA survivor handbook; control group
Number of subjects: 61
Study 29649022 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills and Philosophy
Number of subjects: 298
Study 29649022 — intervention group
Group type: COMPARATOR
Intervention: Skills only
Number of subjects: 298
Study 29649022 — intervention group
Group type: COMPARATOR
Intervention: Philosophy only
Number of subjects: 298
Study 29649022 — intervention group
Group type: COMPARATOR
Intervention: Physical Fitness (Placebo)
Number of subjects: 298
Study 27628038 — intervention group
Group type: EXPERIMENTAL
Intervention: Qing-Xin-Jie-Yu Granules (QXJYG), twice daily for 6 months
Number of subjects: 1500
Study 27628038 — intervention group
Group type: COMPARATOR
Intervention: Placebo granules, twice daily for 6 months
Number of subjects: 1500
Study 24309220 — intervention group
Group type: EXPERIMENTAL
Intervention: IUB (intrauterine ball)
Number of subjects: 15
Study 22909147 — intervention group
Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ (various combinations)
Number of subjects: 2690
Study 22909147 — intervention group
Group type: COMPARATOR
Intervention: OLM/AML (dual therapy)
Number of subjects: 2690
Study 22909147 — intervention group
Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ (40mg/5mg/25mg, 40mg/10mg/12.5mg, 40mg/10mg/25mg)
Number of subjects: 2690
Study 19943833 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medication and interpersonal psychotherapy
Number of subjects: 244
Study 19943833 — intervention group
Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 244
Study 19943833 — intervention group
Group type: EXPERIMENTAL
Intervention: Open treatment with antidepressant medication
Number of subjects: 244
Study 19043609 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of fucose/galactose solution for 21 days
Number of subjects: 11
Study 19043609 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (inhalation and intravenous antibiotics)
Number of subjects: 11
Study 15994852 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 28
Study 15994852 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (in women with HRT)
Number of subjects: 28
Study 15994852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 14616169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Group (omeprazole, clarithromycin, amoxicillin-clavulanic acid intravenously b.d. for 3 days followed by 7 days of oral omeprazole plus placebo)
Number of subjects: 75
Study 14616169 — intervention group
Group type: COMPARATOR
Intervention: Oral Group (intravenous omeprazole plus placebo followed by 7 days of oral omeprazole, clarithromycin and amoxicillin b.d.)
Number of subjects: 75
Study 10805221 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant glycosylated interleukin 6 (rhIL-6) at 1-10 microg/kg/day
Number of subjects: 10
Study 8897118 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 81
Study 8897118 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 81
Study 1325013 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (group HC) with reduced heparin dose of 225 IU/kg
Number of subjects: 14
Study 1325013 — intervention group
Group type: COMPARATOR
Intervention: Noncoated circuits (group C) with standard heparin dose of 300 IU/kg
Number of subjects: 14
Study 1325013 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (group HC)
Number of subjects: 14
Study 1325013 — intervention group
Group type: COMPARATOR
Intervention: Noncoated circuits (group C)
Number of subjects: 14
Study 6189328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/1 trioxsalen bath PUVA therapy
Number of subjects: 22
Study 6189328 — intervention group
Group type: COMPARATOR
Intervention: equipotent methoxsalen bath PUVA therapy
Number of subjects: 22
Study 31801514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention group
Number of subjects: 228
Study 31801514 — intervention group
Group type: COMPARATOR
Intervention: Standard dietary counseling (control group)
Number of subjects: 228
Study 28689006 — intervention group
Group type: COMPARATOR
Intervention: Statin use
Number of subjects: 969
Study 28689006 — intervention group
Group type: EXPERIMENTAL
Intervention: No statin use
Number of subjects: 969
Study 27502769 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 370
Study 27502769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 24399744 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfotiamine
Number of subjects: 0
Study 24399744 — intervention group
Group type: COMPARATOR
Intervention: Thiamine hydrochloride
Number of subjects: 0
Study 23247442 — intervention group
Group type: EXPERIMENTAL
Intervention: Degradable chitin conduit tublization group
Number of subjects: 30
Study 23247442 — intervention group
Group type: COMPARATOR
Intervention: Traditional epineurial neurorrhaphy group
Number of subjects: 30
Study 20561619 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncovered WallFlex stent
Number of subjects: 151
Study 20561619 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered Comvi stent
Number of subjects: 151
Study 17721089 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV vaccine trials
Number of subjects: 0
Study 16231758 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee intake of more than 3 cups per day
Number of subjects: 42
Study 16231758 — intervention group
Group type: COMPARATOR
Intervention: Non-coffee drinking
Number of subjects: 42
Study 12376583 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge meal consumption in subjects with BED
Number of subjects: 42
Study 12376583 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge meal consumption in more-obese subjects with BED
Number of subjects: 42
Study 12376583 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal meal consumption in subjects with BED
Number of subjects: 42
Study 12376583 — intervention group
Group type: EXPERIMENTAL
Intervention: Satiety ratings after binge meals in subjects with BED
Number of subjects: 42
Study 12376583 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake from fat in obese subjects
Number of subjects: 42
Study 10199878 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 26
Study 10199878 — intervention group
Group type: COMPARATOR
Intervention: Pacing
Number of subjects: 26
Study 10199878 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 26
Study 10199878 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological pacing rates
Number of subjects: 26
Study 7784009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadaver dissection course (n=7)
Number of subjects: 13
Study 7784009 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=6)
Number of subjects: 13
Study 1601341 — intervention group
Group type: EXPERIMENTAL
Intervention: Chevron osteotomy alone
Number of subjects: 38
Study 1601341 — intervention group
Group type: EXPERIMENTAL
Intervention: Chevron osteotomy with adductor tenotomy
Number of subjects: 38
Study 2864945 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium bromide administered after pancuronium bromide
Number of subjects: 40
Study 2864945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium bromide administered during vecuronium-induced partial neuromuscular blockade
Number of subjects: 40
Study 30659073 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability (VVV) of fasting blood glucose (FBG) defined as the SD of FBG measurements (≥26.4 mg/dL)
Number of subjects: 4982
Study 30659073 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability (VVV) of fasting blood glucose (FBG) defined as variability independent of the mean (VIM)
Number of subjects: 4982
Study 30659073 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of SD of FBG among individuals without diabetes
Number of subjects: 4982
Study 30659073 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of VIM among individuals without diabetes
Number of subjects: 4982
Study 30327287 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ProGlide/Glubran technique for vascular access-site closure
Number of subjects: 250
Study 26315474 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor smoking ban with not more than 10 cigarettes/day
Number of subjects: 141
Study 26315474 — intervention group
Group type: COMPARATOR
Intervention: Indoor smoking ban with at least 11 cigarettes/day
Number of subjects: 141
Study 26315474 — intervention group
Group type: COMPARATOR
Intervention: Homes without an indoor smoking ban
Number of subjects: 141
Study 26315474 — intervention group
Group type: COMPARATOR
Intervention: Follow-up sample of homes without a ban
Number of subjects: 141
Study 24779384 — intervention group
Group type: COMPARATOR
Intervention: No mention of the funding source or CoI
Number of subjects: 354
Study 24779384 — intervention group
Group type: COMPARATOR
Intervention: Reporting the funding source only
Number of subjects: 354
Study 24779384 — intervention group
Group type: COMPARATOR
Intervention: Reporting the funding source and CoI
Number of subjects: 354
Study 23138807 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 98
Study 23138807 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 98
Study 23138807 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial administration
Number of subjects: 98
Study 23138807 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall time spent on the trial
Number of subjects: 98
Study 19627407 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical massage (MM)
Number of subjects: 60
Study 19627407 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD)
Number of subjects: 60
Study 19627407 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue manipulation (CTM)
Number of subjects: 60
Study 18622248 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1 (including papillary muscles and trabeculae in myocardium)
Number of subjects: 60
Study 18622248 — intervention group
Group type: COMPARATOR
Intervention: Method 2 (excluding papillary muscles and trabeculae from myocardium)
Number of subjects: 60
Study 18622248 — intervention group
Group type: EXPERIMENTAL
Intervention: Papillary muscles and trabeculae mass
Number of subjects: 60
Study 18622248 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference in ejection fraction
Number of subjects: 60
Study 18622248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular mass index
Number of subjects: 60
Study 16420135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT)
Number of subjects: 67
Study 16420135 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical case management (CCM)
Number of subjects: 67
Study 16420135 — intervention group
Group type: EXPERIMENTAL
Intervention: CBGT + CCM
Number of subjects: 67
Study 16420135 — intervention group
Group type: COMPARATOR
Intervention: CBGT
Number of subjects: 67
Study 16420135 — intervention group
Group type: COMPARATOR
Intervention: All 3 conditions
Number of subjects: 67
Study 11838623 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (6 to 8 mg/day)
Number of subjects: 82